

# Current projects funded by DHSC through the UK Vaccine Network Project

Last updated April 2023

The following document includes all projects currently funded by the UK Vaccine Network. Find previously funded projects at 2019 Projects supported by the UK Vaccine Network (publishing.service.gov.uk).

#### **Contents**

Vaccine Development Competition	1
Candidate vaccines and vaccine platform technologies: preclinical stage	2
Candidate vaccines and vaccine platform technologies: clinical stage	2
Vaccines for epidemic diseases	2
Future Manufacturing Research Hub competition	4
One Health competition	4
Epidemiology for Vaccinology competition	5
Development of vaccine candidates	5

#### **Vaccine Development Competition**

Projects delivered through the Innovate UK managed Vaccine Development Competition

Project title	Lead research organisation	Cost
Phase I study of a MVA based vaccine for Crimean Congo Haemorrhagic fever	United Kingdom Health Security Agency (UKHSA)	£1,106,708

# Candidate vaccines and vaccine platform technologies: preclinical stage

Projects delivered through Innovate UK managed competition to develop candidate vaccines and vaccine platform technologies at the preclinical stage – stage 2

Project title	Lead research organisation	Cost
Clinical trial of a DIOS trivalent Haemorrhagic Fever vaccine (DIOS-HFVac3)	University of Cambridge	£2,349,926
Development of a novel vaccine to protect against Q fever epidemics: late stage preclinical formulation and progression to clinical trial	Oxford Vaccine Group	£1,162,744

# Candidate vaccines and vaccine platform technologies: clinical stage

Projects delivered through Innovate UK managed competition to develop candidate vaccines and vaccine platform technologies at the clinical stage

Project title	Lead research organisation	Cost
Clinical development of a new vaccine for rapid response against Plague: GMP	Oxford Vaccines Group	£3,093,439.00

#### Vaccines for epidemic diseases

Projects delivered through Innovate UK managed competition to develop vaccines for epidemic diseases: Readiness for clinical development and regulatory submission

Project title	Lead research organisation	Cost
A live attenuated pseudorabies virus vectored Nipah vaccine for enhanced protection in pigs	The Pirbright Institute	£332,404.90
GMP Manufacture of a vaccine targeting a viral hemorrhagic fever	University of Oxford	£499,937
A simple, multivalent vaccine to prevent Zika and Chikungunya: progression and readiness to phase II trial	University of Surrey	£497,035
International Serological Standard for Plague	Medicines and Healthcare products Regulatory Agency	£399,821
Pan-coronavirus vaccine	CONSERV BIOSCIENCE LIMITED	£415,262
Development of a subunit vaccine against CCHF virus for use in low-middle income countries; completion of pre-clinical studies	OXFORD EXPRESSION TECHNOLOGIES LIMITED	£377,408
Development of a CD8 T-Cell Priming Vaccine Against Chikungunya Virus	EMERGEX VACCINES HOLDING LIMITED	£490,525
Clinical trial assessment of a multivalent vaccine against Ebola virus	University of Oxford	£371,522.20
A Single-dose DNA vaccine platform to safely induce protective immunity against Zika	University of Nottingham	£462,462
Novel T cell-based vaccine potency assay to accelerate and improve development and manufacturing	OXFORD VACMEDIX UK LIMITED	£492,559
A Peptide-mRNA vaccine for Crimean-Congo Haemorrhagic Fever (CCHF)	PHION THERAPEUTICS LTD	£499,362
Clinical development of the new ChAdOx1 Plague vaccine: A Phase 1b trial in a target population	University of Oxford	£500,000

Project title	Lead research organisation	Cost
Delivering stabilised mRNA to cells for antigen production	John Innes Centre	£499,297
Development of immune assays for CCHF to aid Phase I clinical trials	UKHSA	£426,976
The Protein Forge	THE PROTEIN FORGE LTD	£252,273
Preclinical characterization of a novel vaccine for prevention of Chikungunya	ACTIVIROSOMES LIMITED	£499,800
Phase 1b/2 study of a Modified Vaccinia Ankara vectored Zika vaccine to assess safety in previously flavivirus exposed healthy adults.	University of Liverpool	£487,363
HFVac4: a Quadrivalent Viral Haemorrhagic Fever vaccine for Africa	DIOSYNVAX LTD.	£498,357
Manufacturing saRNA success	Imperial College London	£500,000
Oral Nipah vaccine	IOSBIO LTD	£288,608

### **Future Manufacturing Research Hub competition**

Projects delivered through Engineering and Physical Sciences Research Council (EPSRC) managed Future Manufacturing Research Hub competition

Project title	Lead research organisation	Cost
Future Vaccine Manufacturing Hub	Imperial College London	£9,422,582.79
Vax-Hub	University College London	£13,010,532.00

## One Health competition

Projects delivered through Biotechnology and Biological Sciences Research Council (BBSRC) managed 'One Health' competition

Project title	Lead research organisation	Cost
One Health and accelerating vaccines for Ebola and Lassa (OVEL)	University of Cambridge	£1,475,845.88

## **Epidemiology for Vaccinology competition**

Projects delivered through National Institute for Health Research managed 'Epidemiology for Vaccinology' competition

Project title	Lead research organisation	Cost
Leveraging Pathogen Sequence Data and Adaptive Designs to Improve Vaccine Trials in Emerging Epidemics in LMIC	University of Oxford	£744,463.00

### **Development of vaccine candidates**

Projects delivered through the National Institute for Health and Care Research managed competition for late pre-clinical research and early clinical development of vaccine candidates

Project title	Lead research organisation	Cost
Phase I studies of a novel chimpanzee adenovirus Rift Valley Fever vaccine for humans	MRC Uganda Virus Research Institute, with Jenner Institute, University of Oxford and Pirbright Institute	£1,870,492.00

#### © Crown copyright 2021

#### www.gov.uk/dhsc

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="mailto:nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a>.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

